Abstract
Renal cell carcinoma (RCC) is a relatively frequent cancer with increasing incidence in some regions. There is a need for early diagnosis of this cancer as a significant number of patients develop metastasis in their clinical course. Cancer-testis antigens (CTAs) are a group of tumor associated antigens whose expression has been assessed in a wide range of malignancies. CTAs are also considered as immunotherapy targets. Considering the relative responsiveness of RCC patients to immunotherapy, expression analysis of CTAs in RCC is of clinical importance. However, data regarding expression of CTAs in RCC is scarce except for a few numbers of CTAs including NY-ESO-1. The expression pattern of CTAs in RCC samples and cell lines is reviewed in this manuscript.
Highlights
Renal cell carcinoma (RCC) is among frequent cancers in the world with rising incidence in developing countries
Surgery is recommended for localized RCCs, metastatic RCCs are not cured with this kind of therapy
There are a number of clinical trials evaluating the safety and efficacy of Cancer-testis antigens (CTAs)-based immunotherapeutic approaches in cancer patients
Summary
Renal cell carcinoma (RCC) is among frequent cancers in the world with rising incidence in developing countries. There is a need for development of novel immunotherapeutic approaches for metastatic RCCs. Cancer-testis antigens (CTAs) as a group of tumor associated antigens (TAAs) are considered as appropriate cancer biomarkers as well as immunotherapeutic targets [3]. Cancer Antigen 1 (CAGE1) This CTA has been identified through screening of cDNA expression libraries with serum samples from lung cancer patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
